Forest Laboratories Inc. (FRX): Today's Featured Health Care Loser
Forest Laboratories (FRX) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1%. By the end of trading, Forest Laboratories fell 44 cents (-1.3%) to $34.45 on average volume. Throughout the day, 2.8 million shares of Forest Laboratories exchanged hands as compared to its average daily volume of two million shares. The stock ranged in price between $34.06-$35 after having opened the day at $34.96 as compared to the previous trading day's close of $34.89. Other company's within the Health Care sector that declined today were: Dynacq Healthcare (DYII), down 21.2%, Cormedix (CRMD), down 18.6%, Escalon Medical Corporation (ESMC), down 14.2%, and Biodel (BIOD), down 9.7%. Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $9.18 billion and is part of the drugs industry. The company has a P/E ratio of 9.7, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 14.6% year to date as of the close of trading on Thursday. Currently there are seven analysts that rate Forest Laboratories a buy, three analysts rate it a sell, and 13 rate it a hold. TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share.
- You can view the full Forest Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about FRX
-
July Options Now Available For Forest Laboratories (FRX)
01:56PM 05/20/13
-
Analysts' Actions: MU BSX CVC FRX
08:45AM 05/10/13
-
Ironwood's Constipation Drug Sales Disappoint
08:18AM 04/23/13
-
Notable Two Hundred Day Moving Average Cross - FRX
04:13PM 04/16/13
-
Forest Laboratories Becomes #183 Most Shorted S&P 500 Component, Replacing Allergan
03:00PM 04/10/13
-
Ziopharm Considers Options After Drug Failure
12:02PM 03/27/13
-
Stock Futures Slide as Traders Eye Earnings
09:01AM 01/15/13
Latest from TheStreet Wire
-
Time Warner Cable Inc (TWC): Today's Featured Services Laggard
05:01PM 05/20/13
-
Time Warner Inc (TWX): Today's Featured Media Laggard
05:01PM 05/20/13
-
Bed Bath & Beyond Inc. (BBBY): Today's Featured Retail Laggard
05:01PM 05/20/13
-
Automatic Data Processing (ADP): Today's Featured Technology Laggard
05:01PM 05/20/13
-
NextEra Energy Inc (NEE): Today's Featured Utilities Laggard
05:01PM 05/20/13
-
Intuit Inc. (INTU): Today's Featured Computer Software & Services Laggard
05:01PM 05/20/13
-
PepsiCo Inc (PEP): Today's Featured Consumer Goods Laggard
05:01PM 05/20/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
